Free Newsletter
SPOTLIGHT: FDA gives nod to new Plavix dose
Sanofi-Aventis and Bristol-Myers Squibb announced that they'd nabbed FDA approval for a new 300 mg strength of the anti-clotting drug Plavix, for use as a loading dose when heart patients come into the ER. Release
More stories about FDA approval
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment